SELLAS Life Sciences Group, Inc.
SLS
$12.78
$0.423.40%
NASDAQ
| 06/30/2026 | 03/31/2026 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | -18.58% | 70.02% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 4.07% | 29.31% | |||
| Operating Income | -4.07% | -29.31% | |||
| Income Before Tax | -14.25% | -9.78% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -14.25% | -9.78% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -14.25% | -9.78% | |||
| EBIT | -4.07% | -29.31% | |||
| EBITDA | -- | -- | |||
| EPS Basic | -4.31% | 10.15% | |||
| Normalized Basic EPS | 6.89% | -5.17% | |||
| EPS Diluted | -4.31% | 10.15% | |||
| Normalized Diluted EPS | 6.89% | -5.17% | |||
| Average Basic Shares Outstanding | 9.68% | 22.10% | |||
| Average Diluted Shares Outstanding | 9.68% | 22.10% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||